Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|November 26, 2015

KTN Launches UK Medicines Manufacturing Landscape Portal

The portal is an interactive tool that pulls together the innovation landscape, company base, and manufacturing sites for the entire medicines sector in the UK.

The Knowledge Transfer Network (KTN), the United Kingdom’s innovation network, announced the launch of a new web portal that outlines the UK’s strengths and capabilities in medicines manufacturing.

KTN’s Medicines Manufacturing Landscape portal is an interactive tool that pulls together the innovation landscape, company base, and manufacturing sites for the entire medicines sector in the UK. The platform was developed by KTN on behalf of the Medicines Manufacturing Industry Partnership (MMIP) to address confusion about medicines manufacturing activities in the UK.

The MMIP was jointly established by the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) and includes partners such as Actavis (Allergan plc), AstraZeneca, Eisai, Fujifilm Diosynth Biotechnologies, GlaxoSmithKline, KTN, ReNeuron, and Pfizer. This partnership was formed to strengthen collaboration between the industry and the government in making the UK an attractive and innovation-driven country for medicines manufacturing.

Source: KTN


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.